Back

    Investors

    Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

    Letter from the CEO

    On June 23, 2022, we launched our new company brand, Mendus, emphasizing an even greater focus on changing the course of cancer treatment than ever before in our history. What will really change the course of cancer treatment in the following decades? Mendus will strive to push the boundaries for delaying or preventing tumor recurrence with novel maintenance therapies in AML, ovarian cancer, GIST and over time hopefully in many more forms of cancer. All of this with products that benefit from an excellent safety profile, aiming to minimize damage to health and quality of life.

    To read the full letter from the CEO, please click here.

    Investor Downloads

    Latest Company Presentation

     

    Latest press releases

    Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

    Learn more

    Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)

    Immunicum announced that it has been granted an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST).
    Learn more

    Upcoming Events

    Sachs 22nd Annual Biotech in Europe Forum

    The 22nd Annual Biotech in Europe Forum will take place in-person on September 21-22, 2022, at the Mövenpick Hotel in Basel, Switzerland. Mendus' CEO Erik Manting will present on September 21, 2022.
    Learn more

    Pareto Securities’ 13th Annual Healthcare Conference

    On 7-8 September 2022, Pareto Securities will host its 13th Annual Healthcare Conference. Mendus' CEO Erik Manting will present at the conference.
    Learn more

    Contact

    Telephone

    +46 (0)8 732 8400

    Email

    info@mendus.com

    Head Office

    Västra Trädgårdsgatan 15
    111 53 Stockholm
    Sweden

    R&D Offices

    Emmy Noetherweg 2K
    2333 BK Leiden
    The Netherlands

    Gothenburg Office

    Mendus C/O AstraZeneca BioventureHub
    Pepparedsleden 1
    431 83 Mölndal

    News & events

    At Mendus, we share a strong commitment to improve the lives of people with cancer.

    News & Events